Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos

Angiogenesis is a fundamental developmental process and a hallmark of cancer progression. Receptor tyrosine kinases (RTK) are targets for cancer therapy which may include their action as anti-angiogenic agents. Derazantinib (DZB) is an inhibitor of the fibroblast growth factor receptors (FGFRs) 1–3...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotini, Maria P., Bachmann, Felix, Spickermann, Jochen, McSheehy, Paul M., Affolter, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824571/
https://www.ncbi.nlm.nih.gov/pubmed/33396726
http://dx.doi.org/10.3390/ph14010025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824571/
https://www.ncbi.nlm.nih.gov/pubmed/33396726
http://dx.doi.org/10.3390/ph14010025

Ejemplares similares